Select therapeutic use:
Indications for EYLEA:
Neovascular (wet) age-related macular degeneration (AMD). Macular edema following retinal vein occlusion (RVO). Diabetic macular edema (DME). Diabetic retinopathy (DR) in patients with DME.
Give by intravitreal injection. AMD: 2mg (0.05mL) once every 4 weeks (monthly) for the 1st 3 months, followed by 2mg (0.05mL) once every 8 weeks. RVO: 2mg (0.05mL) once every 4 weeks (monthly). DME or DR with DME: 2mg (0.05mL) once every 4 weeks (monthly) for the 1st 5 injections, followed by 2mg (0.05mL) once every 8 weeks (2 months).
Ocular or periocular infections. Active intraocular inflammation.
Potential risk of arterial thromboembolic events (eg, nonfatal stroke or MI, vascular death). Monitor for endophthalmitis and retinal detachments during the week following injection. Monitor intraocular pressure and perfusion of optic nerve head after injection. Pregnancy (Cat.C). Use effective contraception prior to initial dose, during therapy, and for at least 3 months after last injection. Nursing mothers: not recommended.
Recombinant fusion protein (human VEGF inhibitor + human IgG1).
Conjunctival hemorrhage, eye pain, cataract, vitreous detachment, vitreous floaters, increased intraocular pressure, conjunctival hyperemia, corneal erosion, inj site pain, foreign body sensation in eye.
Vial (for single eye use)—1 (w. needles + syringe)